Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view
- 2 September 2024
- journal article
- review article
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 24 (5) , 1-24
Abstract
MicroRNAs (miRNAs) are a group of small non-coding RNAs and play an important role in controlling vital biological processes, including cell cycle control, apoptosis, metabolism, and development and differentiation, which lead to various diseases such as neurological, metabolic disorders, and cancer. Chemotherapy consider as gold treatment approaches for cancer patients. However, chemotherapeutic is one of the main challenges in cancer management. Doxorubicin (DOX) is an anti-cancer drug that interferes with the growth and spread of cancer cells. DOX is used to treat various types of cancer, including breast, nervous tissue, bladder, stomach, ovary, thyroid, lung, bone, muscle, joint and soft tissue cancers. Also recently, miRNAs have been identified as master regulators of specific genes responsible for the mechanisms that initiate chemical resistance. miRNAs have a regulatory effect on chemotherapy resistance through the regulation of apoptosis process. Also, the effect of miRNAs p53 gene as a key tumor suppressor was confirmed via studies. miRNAs can affect main biological pathways include PI3K pathway. This review aimed to present the current understanding of the mechanisms and effects of miRNAs on apoptosis, p53 and PTEN/PI3K/Akt signaling pathway related to DOX resistance. Graphical Abstract miRNAs involve in DOX resistance according to effecting pathways.Keywords
This publication has 176 references indexed in Scilit:
- Decoding hepatocarcinogenesis from a noncoding RNAs perspectiveJournal of Cellular Physiology, 2023
- miR‐125b lowers sensitivity to apoptosis following mitotic arrest: Implications for breast cancer therapyJournal of Cellular Physiology, 2020
- MicroRNA‐221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signalingCancer Medicine, 2020
- miRNA‐192‐5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase AThe Kaohsiung Journal of Medical Sciences, 2019
- A panel of noncoding RNAs in non–small‐cell lung cancerJournal of Cellular Biochemistry, 2018
- P65‐mediated miR‐590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild‐type p53‐induced phosphatase 1Journal of Cellular Biochemistry, 2018
- MicroRNA‐760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1‐PTEN/Akt Signaling PathwayJournal of Biochemical and Molecular Toxicology, 2018
- Umbelliprenin shows antitumor, antiangiogenesis, antimetastatic, anti‐inflammatory, and immunostimulatory activities in 4T1 tumor‐bearing Balb/c miceJournal of Cellular Physiology, 2018
- Downregulation of miRNA‐128 sensitises breast cancer cell to chemodrugs by targeting BaxCell Biology International, 2013
- MicroRNA‐195 Chemosensitizes Colon Cancer Cells to the Chemotherapeutic Drug Doxorubicin by Targeting the First Binding Site of BCL2L2 mRNAJournal of Cellular Physiology, 2013